alendronate


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to alendronate: Fosamax, alendronate sodium

alendronate

 [ah-len´dro-nāt]
a calcium-regulating agent used in the form of the sodium salt to inhibit resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy; administered orally.

alendronate

/alen·dro·nate/ (ah-len´dro-nāt) a bisphosphonate calcium-regulating agent used in the form of the sodium salt to inhibit the resorption of bone in the treatment of osteitis deformans, osteoporosis, and hypercalcemia related to malignancy.

alendronate

(ə-lĕn′drə-nāt′)
n.
A bisphosphonate drug, C4H13NO7P2, that inhibits bone resorption and is used in the form of its sodium salt to treat and prevent osteoporosis in postmenopausal women.

alendronate

a bone-resorption inhibitor.
indications This drug is used to treat osteoporosis in postmenopausal women and Paget's disease.
contraindication Known hypersensitivity to biphosphonates prohibits the use of this drug.
adverse effects Side effects include anemia, hypokalemia, hypomagnesemia, hypophosphatemia, osteonecrosis of the jaw, abdominal pain, anorexia, constipation, nausea, vomiting, bone pain, hypertension, urinary tract infection, and fluid overload.

alendronate

A biphosphonate used to treat postmenopausal osteoporosis and Paget’s disease of bone. Alendronate reduces vertebral fractures by 48% and other fractures by 21%, increases bone density by 9% and density of the hip bones by 6% over 3 years of therapy.

Adverse effects
Nausea, stomach pain, constipation, diarrhoea, bloating, headaches, dizziness, swelling of joints (especially of hands and feet).

Mechanism of action
Marked inhibition of bone resorption by inhibiting osteoclastic activity and number of osteoclasts by reducing recruitment, and increasing apoptosis.

alendronate

Fosamax® Endocrinology A biphosphonate used to treat postmenopausal osteoporosis and Paget's disease of bone. See Osteoporosis. Cf Salmon calcitonin.

alendronate

A drug used in the prevention and treatment of post-menopausal OSTEOPOROSIS. A brand name is Fosamax.

Alendronate

A nonhormonal drug used to treat osteoporosis in postmenopausal women.
Mentioned in: Osteoporosis

alendronate

(ă-lendrŏ-nāt)
A bisphosphonate drug used to treat osteoporosis.
[coined term based on parts of the chemical name]
References in periodicals archive ?
Conclusion: Our study results suggest that alendronate sodium is a valuable treatment agent for osteoporosis in postmenopausal women.
Alendronate sodium develops fast after entering China, annual sales value rising from less than CNY 30 million in 2005 to CNY 121 million in 2014 and CAGR during this period reaching 18.
1) The agent's manufacturer also warns that alendronate can cause upper gastrointestinal irritation that can lead to esophagitis, esophageal ulcers, and esophageal erosions with bleeding; in rare cases, esophageal stricture or perforation may occur.
Conclusion: The results show that one year administrating testosterone, alendronate, calcium and vitamin D in hypogonadal men can increase BMD significantly in lumbar spine and femoral neck.
The research team incorporated alendronate into the hybrid molecules because once in the bloodstream, it goes directly to the bone surface, where it slows the rate of bone breakdown.
The bone density improvements on 10 mg alendronate were seen in all subgroups of patients but especially in postmenopausal women who were not taking estrogen.
Virtually all patients received alendronate but seven had subsequent treatment with ibandronate or risedronate, whereas one patient received only pamidronate.
The BMD at the time of alendronate discontinuation "was highly predictive of who was going to fracture.
The Lausanne, Switzerland, based drug delivery company EffRx Pharmaceuticals SA (EoACA[pounds sterling]EffRxEoACA[yen]) and its partner, the global pharmaceutical company Nycomed, headquartered in Zurich, Switzerland, today announced that the first European filing for marketing approval of EX101, a once-a-week 70mg buffered effervescent alendronate, for the treatment of osteoporosis, has been submitted.
The licensing agreement for EX101 between Nycomed and EffRx was announced early in 2009 and Nycomed recently amended its original licensing contract with EffRx and now holds exclusive rights to develop, manufacture and commercialise the effervescent formulation of alendronate for the treatment of osteoporosis in all territories in the world except USA and Japan.